PAK 200

structure given in first source; reverses in vivo resistance of tumor cells to adriamycin

Also Known As:

2-(benzyl(phenyl)amino)ethyl-1,4-dihydro-2,6-dimethyl-5-(5,5-dimethyl-2-oxo-1,3,2-dioxaphosphorinan-2-yl)-1-(2-morpholinoethyl)-4-(3-nitrophenyl)-3-pyridine carboxylate; PAK-200; PAK-200S; 3-Pyridinecarboxylic acid, 5-(5,5-dimethyl-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dimethyl-1-(2-(4-morpholinyl)ethyl)-4-(3-nitrophenyl)-, 2-(phenyl(phenylmethyl)amino)ethyl ester, P-oxide, dihydrochloride

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - Dihydropyridines: 214
      - PAK 200: 4

Experts

1.	Akiyama, Shin-ichi: 1 article (04/2002)
2.	Arima, Terukatsu: 1 article (04/2002)
3.	Furukawa, Tatsuhiko: 1 article (04/2002)
4.	Hanada, Shuichi: 1 article (04/2002)
5.	Kreitman, Robert J: 1 article (04/2002)
6.	Masamoto, Izumi: 1 article (04/2002)
7.	Ohno, Nobuhito: 1 article (04/2002)
8.	Saito, Takeshi: 1 article (04/2002)
9.	Sumizawa, Tomoyuki: 1 article (04/2002)
10.	Takeuchi, Shogo: 1 article (04/2002)

Related Diseases

1.	Neoplasms (Cancer) 07/01/1992 - "At 5 microM, PAK-200 enhanced the cytotoxic effect of Adriamycin on drug-sensitive KB-3-1 cells, multidrug-resistant KB-8-5 cells, and two human colorectal carcinoma tumor lines, COK-28LN and COK-36LN, by factors of 2, 5, 2, and 3 times, respectively. " 12/01/1999 - "Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines."
2.	T-Cell Leukemia (Leukemia, T Cell) 04/01/2002 - "PAK-200, FK-506, quinidine, cepharanthine and cyclosporine A (CsA) augmented the ability of the immunotoxin to inhibit protein synthesis in two human T cell leukemia virus type-I infected T cell lines, KUT-1 and KUT-2. "
3.	Colorectal Neoplasms (Colorectal Cancer) 07/01/1992 - "At 5 microM, PAK-200 enhanced the cytotoxic effect of Adriamycin on drug-sensitive KB-3-1 cells, multidrug-resistant KB-8-5 cells, and two human colorectal carcinoma tumor lines, COK-28LN and COK-36LN, by factors of 2, 5, 2, and 3 times, respectively. "
4.	Leukemia 09/01/1992 - "Experiments with P388 and P388/VCR-bearing mice showed that PAK-200 enhanced the effect of vincristine on both leukemia cells in vivo. " 09/01/1992 - "These results suggest that PAK-200 interacts with P-glycoprotein and reverses drug resistance in P388 mouse leukemia cells in vitro, and that PAK-200 has an ability to potentiate the effect of vincristine on P388 mouse leukemia cells in vivo." 09/01/1992 - "Potentiation of the vincristine effect on P388 mouse leukemia cells by a newly synthesized dihydropyridine analogue, PAK-200."

Related Drugs and Biologics

1.	1,4-dihydropyridine (dihydropyridine)
2.	Member 1 Subfamily B ATP Binding Cassette Transporter
3.	Topotecan (Hycamtin)
4.	Cyclosporine (Ciclosporin)
5.	Tacrolimus (Prograf)
6.	Vincristine (Oncovin)
7.	Quinidine (Chinidin)
8.	Proteins (Proteins, Gene)
9.	Doxorubicin (Adriamycin)
10.	Immunotoxins (Immunotoxin)